Abstract
KEY POINTS Recent evidence has highlighted a serious risk of new vertebral compression fractures after discontinuation of the osteoporosis drug, denosumab.[1][1],[2][2] Major societies of bone researchers and clinicians have called for physicians and patients to be made aware of the potential risk
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
